化疗期间同步与序贯启动卵巢功能抑制在绝经前内分泌反应性早期乳腺癌中的探索性分析
该探索性分析基于TEXT和SOFT随机III期试验中1872例接受辅助化疗的激素受体阳性/HER2阴性绝经前乳腺癌患者,比较化疗同步(TEXT,n=1242)与化疗后序贯(SOFT,n=630)启动曲普瑞林卵巢功能抑制的无乳腺癌间期(BCFI)。经倾向评分加权Cox模型分析,同步与序贯启动在总体人群(HR=1.11,95%CI 0.72-1.72;P=0.72;两组4年BCFI均为89%)及<40岁亚组(HR=1.13,95%CI 0.69-1.84)均无显著差异。
要点
- 化疗同步与序贯启动曲普瑞林OFS相比,总体人群无乳腺癌间期无显著差异(HR=1.11,95%CI 0.72-1.72)。
- 两组4年BCFI均为89%,<40岁亚组HR=1.13(95%CI 0.69-1.84)。
- 中位随访约5年,未检测到同步给药的获益或不利影响,但统计效能有限。
核心结论
- 基于TEXT和SOFT约5年中位随访的比较有效性模型,未检测到化疗同步给予OFS对含化疗辅助治疗疗效的有害或有益影响。
- 统计效能有限,尤其是<40岁亚组。
研究设计与样本
- 研究为TEXT和SOFT随机III期试验的探索性分析,纳入1872例接受辅助化疗的激素受体阳性、HER2阴性绝经前乳腺癌患者。
- TEXT组(n=1242)化疗同步启动曲普瑞林,SOFT组(n=630)化疗后序贯启动曲普瑞林。
- 采用landmark分析自化疗末次剂量后1年开始定义BCFI,并采用倾向评分加权Cox模型进行比较有效性分析。
主要发现
- 化疗后中位随访约5年,共231例(12%)乳腺癌事件。
- 总体人群中同步与序贯启动的post-landmark BCFI无显著差异(HR=1.11,95%CI 0.72-1.72;P=0.72),两组4年BCFI均为89%。
- 诊断时<40岁亚组(n=692)中同步与序贯启动的HR=1.13(95%CI 0.69-1.84)。
- 两组辅助化疗中位持续时间均为18周。
关键数值与推荐
- 总体人群:HR=1.11,95%CI 0.72-1.72;P=0.72;4年BCFI两组均为89%。
- <40岁亚组(n=692):HR=1.13,95%CI 0.69-1.84。
- 乳腺癌事件:231例(12%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 为非随机化治疗比较。
- 统计效能有限,尤其<40岁亚组。
- 两组间若干临床病理特征分布存在差异。
- SOFT中化疗后绝经前患者平均更年轻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of adjuvant endocrine therapy. If chemotherapy is also given, it is uncertain whether to select concurrent or sequential OFS initiation. DESIGN AND METHODS: We analyzed 1872 patients enrolled in the randomized phase III TEXT and SOFT trials who received adjuvant chemotherapy for hormone receptor-positive, HER2-negative breast cancer and upon randomization to an OFS-containing adjuvant endocrine therapy, initiated gonadotropin-releasing-hormone-agonist triptorelin. Breast cancer-free interval (BCFI) was compared between patients who received OFS concurrently with chemotherapy in TEXT (n = 1242) versus sequentially post-chemotherapy in SOFT (n = 630). Because timing of trial enrollment relative to adjuvant chemotherapy differed, we implemented landmark analysis re-defining BCFI beginning 1 year after final dose of chemotherapy (median, 15.5 and 8.1 months from enrollment to landmark in TEXT and SOFT, respectively). As a non-randomized treatment comparison, we implemented comparative-effectiveness propensity score methodology with weighted Cox modeling. RESULTS: Distributions of several clinico-pathologic characteristics differed between groups. Patients who were premenopausal post-chemotherapy in SOFT were younger on average. The median duration of adjuvant chemotherapy was 18 weeks in both groups. There were 231 (12%) BC events after post-landmark median follow-up of about 5 years. Concurrent use of triptorelin with chemotherapy was not associated with a significant difference in post-landmark BCFI compared with sequential triptorelin post-chemotherapy, either in the overall population (HR = 1.11, 95% CI 0.72-1.72; P = 0.72; 4-year BCFI 89% in both groups), or in the subgroup of 692 women <40 years at diagnosis (HR = 1.13, 95% CI 0.69-1.84) who are less likely to develop chemotherapy-induced amenorrhea. CONCLUSION: Based on comparative-effectiveness modeling of TEXT and SOFT after about 5 years median follow-up, with limited statistical power especially for the subgroup <40 years, neither detrimental nor beneficial effect of concurrent administration of OFS with chemotherapy on the efficacy of adjuvant therapy that includes chemotherapy was detected. CLINICALTRIALS.GOV: NCT00066690 and NCT00066703.
引用
- Regan MM, Walley BA, Francis PA, et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol. 2017. PMID: 28911092. doi:10.1093/annonc/mdx285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。